Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs.
Sruamsiri, Rosarin; Kameda, Hideto; Mahlich, Jörg.
Drugs Real World Outcomes
; 5(3): 169-179, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30073580
Methotrexate for psoriatic arthritis.
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Etanercept for the treatment of rheumatoid arthritis.
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.